ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Are they fighting a losing battle... or the opposite

<< Previous

Bullboard Posts

Next >>

Comment by Thenorth1990on Jan 18, 2021 4:45pm

302 Views

Post# 32322463

RE:RE:RE:Are they fighting a losing battle... or the opposite

yeah all hope is on a corrupt fda, advocacy groups raised concerns about possible collusion between fda and biogen. I think promis might have some good news on serology test, but they will wait until news on aducamanab comes out , so that the stock is back at .18 ~.22

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks